Do More With Reuters
Partner Services

Side effects mar Elan, Wyeth Alzheimer's trial

Wed Jul 30, 2008 2:30am IST
 
Email | Print | | Single Page
[-] Text [+]

By Julie Steenhuysen

CHICAGO, July 29 (Reuters)- Keenly awaited details on Elan (ELN.I: Quote, Profile, Research) and Wyeth's WYE.N new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, especially in people with a genetic risk of the disease, the companies said on Tuesday.

They said 12 people with mild-to-moderate Alzheimer's, who were treated with the drug, developed a build-up of fluid in the brain called vasogenic edema.

Ten of those cases were in people who have the ApoE4 gene, which significantly raises their risk of developing Alzheimer's disease. The other two were in non-carriers of the gene.

"Usually this occurred after the first or second dose," Dr Ronald Black, assistant vice president in neuroscience research at Wyeth, said in an interview. "About half of them had no symptoms at all, and about a third had minor symptoms."

Black said the side effect appeared to be "strongly related" to the dose of the drug people took. "The higher doses get more," he said.

None of those who received a placebo developed the brain-swelling condition. All those who suffered the side effect recovered from it, Black said.

The update on the antibody medicine, also known as AAB-001, has been closely watched by investors. If proven to work, the drug could be the first to modify the course of Alzheimer's disease, rather than just offering symptom relief.

Some analysts have forecast eventual annual sales of $13 billion.  Continued...

Russian Finance Minister Alexey Kudrin poses with his G20 colleagues and central bank leaders during the family photo at the G20 Finance Ministers meeting at a hotel in St. Andrews, Scotland. REUTERS/POOL New
Pledge to support economies

G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured.  Full Article | Related Story 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

SHOWCASE

Sanjay Sinha
Balancing Act

In India, it is a tough choice between growth, managing inflation and financial stability.  Full Article 

 
Nipun Mehta
Road to Recovery

There needs to be an acceptable balance created between education and healthcare and infrastructure spend, says Nipun Mehta of SG Private Banking.   Full Article 

 
Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article